Note: Descriptions are shown in the official language in which they were submitted.
CA 02343806 2001-03-12
WO 00/15274 PCT/GB99/030I3
- 1 -
COLLAGENOUS TISSUE COMPOSITIONS
This invention relates to collagenous tissue
compositions.
In recent years, much attention has been given to the
development of compositions and preparations for wound
treatment and for use in genEral and plastic surgery, in
particular for the improved restoration of surgically
induced wounds or for the correction of physiological
malfunction as, for example, of the urethral sphincter
in cases of urinary incontinence.
Much attention has been focussed on the provision of
materials based on collagen, either of human or animal
origin. In particular, considerable attention has been
directed to developing preparations and materials based
on animal tissues which are treated to provide
compatibility, i.e. to avoid rejection of the tissues
when used on humans.
Earlier work by the inventors of the present application
is reflected in United States Patent Specification
5397353 and EP-A-182842 which disclose methods of
CA 02343806 2001-03-12
WO 00/15274 PCT/GB99/03013
- 2 -
preparing collagenous materials, preferably in sheet
form, and which are suitable for transplantation. The
treatment is designed to produce a collagenous material
which is non-antigenic so that it is not rejected and
5 which is non-resorbable so that it forms a permanent
transplant. In particular, the material described in
these specifications retains the natural structure and
original architecture of the natural tissue; the
molecular ultrastructure of the collagen is retained.
10 These materials have proved highly satisfactory in
practice and, in particular, have shown themselves to be
capable of being re-vascularised once implanted while,
at the same time, being resistant to calcification.
They are particularly useful in ear, nose and throat,
15 orthopaedic, gynaecological and urological procedures
and a range of hernia repairs including parastomal
incisional and inguinal hernias.
The compositions described in United States Patent
20 Specification 5397353, however, are disclosed as large
scale structures, for example 0.75 mm thick and usually
presented as sheets varying in size from 25 cm2 to 50
cmz. This is useful for specific .implant use, e.g.
during restorative surgery, but is not always suited for
25 use generally to build up soft tissues.
In cosmetic and reconstructive surgery, e.g. for the
repair of small acne scars and for elevating and
smoothing wrinkles, it is often desirable to use
30 material in another form for tissue implantation or so-
called augmentation which can be injected or otherwise
introduced into the desired site.
Various so-called injectable implant materials have been
35 developed for such purposes. United States Patent
Specifications 5523291, 5676698 and 5705488 disclose
CA 02343806 2001-03-12
WO 00/15274 PCTIGB99/03013
- 3 -
injectable implant compositions for soft tissue
augmentation comprising elastin and collagen and a
biocompatible carrier, or flexible pouches containing
such a material. The difficulty with such materials as
5 are disclosed in these United States specifications,
however, is that there is a tendency to resorption and
this can mean that the implant is effective only for a
limited time. Additionally, such materials do not
encourage vascularisation, i.e. they do not integrate
10 well into the surrounding healthy tissue following
implantation.
Furthermore, in wound surgery, e.g. for repairing bullet
wounds or injuries caused by machinery or vehicle
15 accidents and indeed following incisional injury, there
is often a problem in that tissue .is lost from the wound
area. This leads to the development of scars, which may
be hyperplastic and disfiguring and lead to impaired
body function.
Scars arise from the biological response of adult
connective tissue to injury. Unlike foetal tissues
which respond to incision or injury by regenerating new
dermis to replace the lost/damaged tissue (i.e. bridging
25 the defect with dermal collagen fibres with normal
dermal collagen architecture) after birth, equivalent
wounds are repaired rather than regenerated and the
wound becomes filled with scar tissue. Thus the
bridging tissue after birth does not replicate the
30 original normal dermal architecture. During the repair
process, f ibroblasts (the cells which permeate all
connective tissues and which synthesise the extra-
cellular matrix including structural collagen) and small
blood vessels migrate into the wound space to form
35 highly cellular granulation tissue which transforms into
the dense irregularly organised collagen mass described
CA 02343806 2001-03-12
WO 00/15274 PCT/GB99/03013
- 4 -
as scar tissue.
One solution to this particular tissue loss problem has
been to apply three-dimensional collagen gels within the
5 lost tissue area of the wound which subsequently acts as
a matrix network for the growth of so-called histiotypic
skin. The collagen used to form this particular gel is
completely water-soluble and when it is applied, it is
invaded with fibroblasts and small blood vessels, water
10 is extruded and a fragile gel is formed in which the
collagen molecule is polymerised to form collagen
fibrils. Although reasonably successful in rebuilding
the lost tissue in the area around the original wound,
the initial three-dimensional matrix formed from the
15 collagen gel does not replicate the normal matrix
architecture of the body's natural tissue and, as such,
the gel has no inherent stability. This inherent
instability leads to the gel being rapidly re-absorbed
by the body and replaced with scar-like tissue.
Other recent proposals to overcome the problem of scar
tissue formation have involved the extremely difficult
(and very expensive) use of monoclonal antibodies to
suppress the action of growth factors such as
transforming growth factor (TGF - ~3).
We have now surprisingly found that the favourable
properties, including resistance to resorption,
resistance to calcification, granulation and the ability
30 to become recellularized and revascularised, which
characterise the large scale structures disclosed in
Specification 5397353, are capable of being retained if
the collagen material is presented in mouldable form at
the fibre fragment level of organisation, where it can
35 be used as a wound filler, or in injectable form for use
in cosmetic and reconstructive surgery.
CA 02343806 2005-05-05
-5-
According broadly to the present invention there is provided an
implant composition which comprises a biocompatible carrier medium
having dispersed therein particles of collagenous material, where
the particles comprise fragments of collagenous fibres and are
thus sufficiently large to preserve the original architecture and
molecular structure of the natural tissue material from which they
are derived, and wherein the collagenous material is substantially
free of non-fibrous tissue proteins, glycoprot;eins, cellular
elements and lipids or lipid residues, and which is non-cytotoxic.
Preferably, the material is free or substantially free of
antigenic polysaccharides and mucopolysaccharides. The
biocompatible medium may be, for example, a saline or dextran or
hyaluronic acid solution.
Such compositions may vary widely in consistency. For example, if
the particle size and concentration in the biocompatible medium is
such as to produce a fairly liquid suspension, this can be
injectable provided the particles are not too large. More
concentrated thicker consistency compositions may be used as pasty
wound filling compositions.
Such materials may be prepared from collagenous materials of human
or animal origin, the preferred starting material being pig
dermis, by methods as disclosed in U.S. Patent. No. 5,397,353 or
analogously thereto. Depending on the starting material, the
composition may contain a proportion of elastin. It is then
possible, provided care is taken, to reduce th.e material from
large pieces to small particles which can then be formulated into
a sterile injectable composition or a sterile wound filling paste.
In order to produce a collagen paste with appropriate
CA 02343806 2001-03-12
WO 00/15274 PCT/GB99/03013
- 6 -
density and rheological properties (flow rate and an
ability to retain shape after moulding), a suspension of
collagenous particles in a suitable carrier can be
prepared to form a controllable concentration of the
composition.
Care must however be taken to ensure that the size
reduction of the starting material is not accompanied by
degradation of the molecular structure of the original
10 material. The preferred method of providing particles
of an appropriate size is by grinding or milling and
this is preferably carried out in a ball or hammer mill
which may be cooled to an appropriate temperature.
Milling may be carried out in dry form (less than 10~
15 moisture content) or in frozen hydrated form (20 - 80~
moisture content).
Collagen which has been milled in a frozen hydrated
state may be dehydrated by acetone extraction, freeze
20 drying or in a current of air. The dry collagen powder
may be suspended in an essentially non-aqueous, non-
toxic, bio-compatible medium, such as for example,
glycerol prior to injection.
25 An anaesthetic as for example, lignocaine may be
incorporated into the composition.
The collagenous material may be, if desired,
30 crosslinked, e.g. using a diisocyanate, in order to make
it resistant to collagenolytic enzymes and thus render
it substantially non-resorbable.
The preferred method of rendering the compositions
35 sterile is by gamma irradiation.
CA 02343806 2001-03-12
WO 00/15274 PCT/GB99/03013
_ 7 _
The preferred particle size of the particles of
collagenous material in the injectable compositions
according to the present invention is from 50 to 500
microns. The particle size distribution may vary but
5' preferably at least 50~ of the particles are within ~
35~ of the average particle size. The concentration of
solids in the injectable composition is preferably in
the range of 10 to 70$ (w/v). In contrast, in the pasty
wound filling compositions, the concentration of solids
is generally up to 80$.
The efficacy of the compositions of the invention can be
seen in vitro. It has been observed that when dispersed
collagen fibre fragments (milled collagen) are seeded
15 with human or rodent fibroblasts i.n tissue culture, the
fibroblasts attach to the collagen fragments and
aggregate them to form dense tissue like discs which are
easily manipulable.
20 Furthermore, when injected in viva, milled collagen is
rapidly invaded by fibroblasts and small blood vessels
(much more rapidly than collagen sheets) to form a new
tissue in which the collagen fibre fragments are
organised into intermeshing collagen fibres similar to
25 normal dermal collagen architecture, i.e. are not
resorbed and do not form scar tissue.
The injectable compositions can be used in a variety of
clinical situations. For example, to control urinary
30 incontinence and more specifically in intrinsic
sphincter deficiency, by peri-urethral injection to
reduce lumen aperture. Cosmetic applications include
the use of injection of collagenous suspensions
following eyebrow uplift, for lip augmentation and to
35 rectify facial defects, frown lines and acne scars. As
another example, in arthritic joints, there is often a
CA 02343806 2001-03-12
WO 00/15274 PCT/GB99/03013
_ g _
marked loss and damage of the smooth cartilage layer
which consists of chrondrocytes supported by a fibrous
collagen matrix. There is evidence that under the
inflammatory conditions in arthritic joints that
5 collagenase is produced which destroys the collagen
matrix of the cartilage layer. If a collagenous
suspension according to the invention is injected into
the joint, it may assist in producing a collagenase
resistant matrix to support chrondrocytes and so repair
the damage.
An alternative clinical scenario is where it is
necessary to treat a large area of skin, for example,
the back of the hand or neck in elderly patients where
15 the skin has become very thin. A multi-point injection
system may be employed for this purpose. Such a system
may combine a number of needles mounted in a hollow
block of metal or plastics material, the inlet of which
is fed with collagenous suspension with a syringe,
20 metering pump, piston peristaltic pump or any other
suitable device.
The collagenous compositions of the invention may also
be used for the purpose of supressing scar formation in
25 surgical wounds, the milled collagenous material again
serving to introduce fibre-structured fragments into the
wound space immediately during or after closing the
wound by suture or tape. Although totally against
convention, such a procedure has been shown to be
30 extremely beneficial. The introduction of the
collagenous material fragments into newly-formed wounds,
e.g. incisional spaces, provides an anatomically "thin"
matrix of collagen-rich sites for the fibroblasts and
small blood vessels to migrate in to from the wound
35 edges. This has a profound influence on the behaviour
of the fibroblasts as within such a collagen-rich
CA 02343806 2001-03-12
WO 00/15274 PCT/GB99/03013
_ g _
environment within the wound space, they do not receive
the signals to produce granulation tissue and synthesise
excess new collagen. In other words scar formation is
largely suppressed. This simple "mechanical" approach
5 differs from the prior art, in particular the use of
monoclonal antibodies as it is far simpler to apply and
far cheaper.
10 Use of milled collagen by injection through fine needles
is somewhat limited because of the mode of introduction
of collagenous material to the site where it is needed.
However, the thicker consistency compositions, which
allow the use of a wider spectrum of collagenous
15 material fragment sizes, can be used in a variety of
situations where an injectable material would not be
suitable. Thus in the treatment of more extensive or
severe wounds, in order to replace lost tissue and to
greatly reduce the formation of scar tissue, collagen
20 fibre fragments may be introduced as a pasty composition
into the wound space before applying an appropriate
dressing or closure by suture or tape. For example, the
composition may be used for immediate reconstruction
following breast lumpectomy. For skin-loss defects,
25 including those following traumatic chemical or burn
injury, or those presented by leg ulcers, the pasty
composition may be used to replace lost dermis with
appropriate cover and dressing.
30 The following examples will serve to illustrate the
invention:
Example 1
35 Under sterile conditions, samples of porcine dermal
collagen were cut into small pieces (1 to 3 mm3) and
CA 02343806 2005-05-05
-10-
dehydrated using several changes of 100% ethanol and anhydrous
acetone. Using a ball mill, the dried collagen pieces were ground
and sieved to produce a fine white powder. The sieved powdered
collagen was rehydrated in sterile phosphate buffered saline to
produce a collagen suspension concentration of 60 to 70°s (w/v).
Example 2
Small pieces of blotted porcine collagen were frozen in liquid
nitrogen and ground in a cryogenic mill. The ground collagen
fragments were suspended in sterile phosphate buffered saline to
produce a collagen suspension concentration o:E 60 to 70o (w/v).
Example 3
To directly examine cell/collagen biointeraction, sieved powdered
porcine dermal collagen was rehydrated in complete mammalian cell
culture medium to produce a collagen suspension concentration of
70% (w/v) and seeded with either primary human foreskin
fibroblasts or primary rat skin dermal fibrobl_asts.
Collagen/fibroblast samples were aliquoted into Costar* wells
and incubated at 37°C, 5 to 7% (w/v) COZ saturated humidity.
As studied over a 21 day incubation period, bath human and rat
fibroblasts proliferated and migrated into and adhered to the
porcine collagen fragments which they assembled into densely
packed clumps or discs.
Example 4
To examine in vivo performance collagen suspensions were injected
(0.2 ml/injection) through a 21 gauge needle intracutaneously into
dorsal sites in isogenic PVG/Ola
*Trade-mark
CA 02343806 2001-03-12
WO 00/15274 PCT/GB99/03013
- 11 -
rats. Sequential biopsies up to 12 month post injection
showed the persisting macroscopic presence of injected
collagen as subdermally located white discs with no
overt signs of loss of injected collagen mass nor of
5 adverse host reactions. Early biopsies showed that the
injected collagen remains in situ and within 9 days is
fully invaded with fibroblasts and small blood vessels.
Subsequent histology showed that the collagen fibre
fragments are organised into intermeshing collagen
10 fibres to produce a tissue with an architecture
resembling normal dermal collagen.
Example 5
15 Under sterile conditions, samples of porcine dermal
collagen produced in accordance with the process
described in US-A-5397353 were cut into small pieces (1
to 3 mm'), frozen in liquid nitrogen and ground in a
cryogenic mill. The ground collagen fragments were
20 suspended in sterile phosphate buffered saline to
produce a pasty composition with a solids content of
80$w/v.
Example 6
Pockets were made in the skin of the pinnae of PG/Ola
rats, the collagen paste composition inserted with a
spatula and the wounds closed and secured with a spray
dressing. Sites of collagen insertion were biopsied at
30 monthly intervals for histological examination. Over a
period of 6 months, the collagen implants which
persisted as raised skin bumps, became incorporated into
surrounding host tissues and no adverse effects were
found.
Example 7
CA 02343806 2001-03-12
WO 00/15274 PCT/GB99/03013
- 12 -
1 ml of the collagen paste was injected by "trocar" or
large bore needle subdermally in the dorsum of PVG/Ola
rats. This "soft tissue filler" persisted with no
adverse host reactions over a period of six months.
5
Example 8
Full-thickness incisional skin wounds were made in the
dorsum of PVG/Ola rats. The wounds were closed using
10 interrupted sutures and a suspension of collagen
composition was injected into the wounds until it
extruded above the wound surface. Wounds were biopsied
at 6, 8, 10 and 14 days for histological examination
which revealed evidence of incisional healing in the
15 absence of observable scar tissue.
Example 9
The collagen paste composition, with or without prior
20 seeding with isogenic fibroblasts in culture, was used
to fill 1 x lcm full-thickness excised skin wounds in
PVG/Ola rats and covered with a semi-permeable membrane
(Opsite - REGISTERED TRADE MARK) as a primary dressing.
Subsequent observation and histology revealed that the
25 implanted collagen composition becomes covered by
migrating epithelium from the wound margins within 28
days and acts as an effective and persisting dermal
replacement.
30
